Josef S Smolen

发表

Association of joint space narrowing with impairment of physical function and work ability in patients with early rheumatoid arthritis: protection beyond disease control by adalimumab plus methotrexate

D. M. van der Heijde, R. Landewé, E. Keystone, 2012, Annals of the rheumatic diseases.

Criteria for early rheumatoid arthritis: from Bayes' law revisited to new thoughts on pathogenesis.

P. Lipsky, F. Breedveld, T. Huizinga, 2002, Arthritis and rheumatism.

Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial.

John Han, Daniel Baker, Paul Emery, 2006, Arthritis and rheumatism.

Concise Report

Tsutomu Takeuchi, Désirée van der Heijde, Maxime Dougados, 2005 .

Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients.

E. Keystone, J. Smolen, D. Aletaha, 2007, Arthritis and rheumatism.

Early rheumatoid arthritis

Tanja Stamm, J. Smolen, D. Aletaha, 2006, Current opinion in rheumatology.

Physical disability in rheumatoid arthritis is associated with cartilage damage rather than bone destruction

J. Smolen, D. Aletaha, J. Funovits, 2011, Annals of the rheumatic diseases.

New therapies for treatment of rheumatoid arthritis

Michael H Weisman, Paul Emery, M. Weisman, 2007, The Lancet.

Characterization and Analysis of the Proximal Janus Kinase 3 Promoter1

Martin Aringer, D. Kastner, M. Aringer, 2003, The Journal of Immunology.

Validating the International Classification of Functioning, Disability and Health Comprehensive Core Set for Rheumatoid Arthritis from the patient perspective: a qualitative study.

Alarcos Cieza, Gerold Stucki, A. Cieza, 2005, Arthritis and rheumatism.

UvA-DARE (Digital Academic Repository) American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials

David T Felson, Maxime Dougados, Peter Tugwell, 2011 .

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

Désirée van der Heijde, Maurizio Cutolo, Laure Gossec, 2013, Annals of the rheumatic diseases.

The assessment of disease activity in rheumatoid arthritis.

J. Smolen, D. Aletaha, Daniel Aletaha, 2010, Clinical and experimental rheumatology.

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

John Wong, Désirée van der Heijde, Maurizio Cutolo, 2010, Annals of the rheumatic diseases.

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update

Tsutomu Takeuchi, René Westhovens, Tanja Stamm, 2010, Annals of the rheumatic diseases.

The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now?

J. Smolen, D. Aletaha, K. Redlich, 2008, Arthritis research & therapy.

Activation of p38 MAPK is a key step in tumor necrosis factor-mediated inflammatory bone destruction.

Georg Schett, J. Zwerina, G. Schett, 2006, Arthritis and rheumatism.

Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA)

Jonathan Kay, Gabriel Maciel, Maxime Dougados, 2013, Annals of the rheumatic diseases.

EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis

Désirée van der Heijde, Iain Watt, Philip G Conaghan, 2013, Annals of the rheumatic diseases.

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update

Tsutomu Takeuchi, René Westhovens, Désirée van der Heijde, 2020, Annals of the Rheumatic Diseases.

Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis

Laure Gossec, Maxime Dougados, Tore K Kvien, 2010, Annals of the rheumatic diseases.

Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis

Tsutomu Takeuchi, Ran Liao, Tsu-Yi Hsieh, 2020, RMD Open.

Treating rheumatoid arthritis to target: recommendations of an international task force

Maurizio Cutolo, Maxime Dougados, Maarten, 2010, Annals of the rheumatic diseases.

Minimal disease activity for rheumatoid arthritis: a preliminary definition.

David T Felson, Maxime Dougados, Claire Bombardier, 2005, The Journal of rheumatology.

Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis

Laure Gossec, Sofia Ramiro, Paul Emery, 2014, Annals of the rheumatic diseases.

Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis

Laure Gossec, Sofia Ramiro, R. Landewé, 2014, Annals of the rheumatic diseases.

Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states.

Tanja Stamm, Michael M Ward, M. Ward, 2005, Arthritis and rheumatism.

Application of the 2010 ACR/EULAR classification criteria in patients with very early inflammatory arthritis: analysis of sensitivity, specificity and predictive values in the SAVE study cohort

R. Landewé, T. Huizinga, J. Smolen, 2012, Annals of the rheumatic diseases.

Reliability of patient-reported outcomes in rheumatoid arthritis patients: an observational prospective study.

Tanja Stamm, J. Smolen, D. Aletaha, 2016, Rheumatology.

A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis.

Nathan Vastesaeger, E. S. St. Clair, J. Smolen, 2009, Rheumatology.